FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048507165> ?p ?o ?g. }

• W2048507165 endingPage "889" @default.
• W2048507165 startingPage "883" @default.
• W2048507165 abstract "To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with myeloid metaplasia (MMM).We analyzed (March 1999 to August 2003) initial and long-term outcomes from 36 patients with symptomatic MMM who had enrolled in either our thalidomide single-agent trial (n=15) or our trial of low-dose thalidomide (50 mg/d) combined with prednisone (n=21).Among the 36 study patients, 20 (56%) showed some improvement in their clinical course. Response rates for specific end points included improvements in anemia (15 of 36 [42%]), thrombocytopenia (10 of 13 [77%]), or splenomegaly (5 of 30 [17%]). The combination of low-dose thalidomide and prednisone, as opposed to single-agent thalidomide, was better tolerated and more efficacious. After a median follow-up of 25 months (range, 20-56 months), 10 of 36 patients (28%) showed an ongoing response, including 8 patients in whom protocol treatment has been discontinued for a median of 21 months (range, 16-31 months). Durable treatment responses were documented for only anemia and thrombocytopenia. Treatment response was not affected by the baseline status of bone marrow fibrosis, angiogenesis, osteosclerosis, cytogenetics, or circulating myeloid progenitor (CD34) cell count. Unusual drug effects, all reversible, included leukocytosis (8 patients) and/or thrombocytosis (6 patients).Thalidomide (alone or combined with prednisone) is an effective first-line treatment of symptomatic anemia or thrombocytopenia in MMM. Thalidomide-based therapy has the potential to produce durable responses in MMM-associated cytopenias, even after discontinuation of the drug." @default.
• W2048507165 created "2016-06-24" @default.
• W2048507165 creator A5016216479 @default.
• W2048507165 creator A5025859771 @default.
• W2048507165 creator A5039057642 @default.
• W2048507165 creator A5064374340 @default.
• W2048507165 date "2004-07-01" @default.
• W2048507165 modified "2023-09-23" @default.
• W2048507165 title "Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia" @default.
• W2048507165 cites W135049235 @default.
• W2048507165 cites W1970343951 @default.
• W2048507165 cites W1973882186 @default.
• W2048507165 cites W1985147506 @default.
• W2048507165 cites W1991976737 @default.
• W2048507165 cites W1994175709 @default.
• W2048507165 cites W1998584331 @default.
• W2048507165 cites W2000799069 @default.
• W2048507165 cites W2005491291 @default.
• W2048507165 cites W2005605485 @default.
• W2048507165 cites W2007552143 @default.
• W2048507165 cites W2028705933 @default.
• W2048507165 cites W2043212698 @default.
• W2048507165 cites W2048470652 @default.
• W2048507165 cites W2060487016 @default.
• W2048507165 cites W2066567885 @default.
• W2048507165 cites W2080024052 @default.
• W2048507165 cites W2087171330 @default.
• W2048507165 cites W2117327010 @default.
• W2048507165 cites W2120161314 @default.
• W2048507165 cites W2121122463 @default.
• W2048507165 cites W2125469922 @default.
• W2048507165 cites W2125559109 @default.
• W2048507165 cites W2127206962 @default.
• W2048507165 cites W2144531125 @default.
• W2048507165 cites W2159746652 @default.
• W2048507165 cites W2168663436 @default.
• W2048507165 cites W2316160054 @default.
• W2048507165 cites W2326795317 @default.
• W2048507165 cites W2396372492 @default.
• W2048507165 cites W3041047318 @default.
• W2048507165 cites W3114368461 @default.
• W2048507165 cites W4237139322 @default.
• W2048507165 cites W4251021052 @default.
• W2048507165 cites W4252869137 @default.
• W2048507165 doi "https://doi.org/10.4065/79.7.883" @default.
• W2048507165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15244384" @default.
• W2048507165 hasPublicationYear "2004" @default.
• W2048507165 type Work @default.
• W2048507165 sameAs 2048507165 @default.
• W2048507165 citedByCount "58" @default.
• W2048507165 countsByYear W20485071652012 @default.
• W2048507165 countsByYear W20485071652013 @default.
• W2048507165 countsByYear W20485071652014 @default.
• W2048507165 countsByYear W20485071652015 @default.
• W2048507165 countsByYear W20485071652016 @default.
• W2048507165 countsByYear W20485071652017 @default.
• W2048507165 countsByYear W20485071652018 @default.
• W2048507165 countsByYear W20485071652019 @default.
• W2048507165 countsByYear W20485071652020 @default.
• W2048507165 countsByYear W20485071652021 @default.
• W2048507165 crossrefType "journal-article" @default.
• W2048507165 hasAuthorship W2048507165A5016216479 @default.
• W2048507165 hasAuthorship W2048507165A5025859771 @default.
• W2048507165 hasAuthorship W2048507165A5039057642 @default.
• W2048507165 hasAuthorship W2048507165A5064374340 @default.
• W2048507165 hasConcept C126322002 @default.
• W2048507165 hasConcept C141071460 @default.
• W2048507165 hasConcept C2776364478 @default.
• W2048507165 hasConcept C2778248108 @default.
• W2048507165 hasConcept C2778720950 @default.
• W2048507165 hasConcept C2779282312 @default.
• W2048507165 hasConcept C2779609412 @default.
• W2048507165 hasConcept C2780007613 @default.
• W2048507165 hasConcept C2780076729 @default.
• W2048507165 hasConcept C71924100 @default.
• W2048507165 hasConcept C90924648 @default.
• W2048507165 hasConceptScore W2048507165C126322002 @default.
• W2048507165 hasConceptScore W2048507165C141071460 @default.
• W2048507165 hasConceptScore W2048507165C2776364478 @default.
• W2048507165 hasConceptScore W2048507165C2778248108 @default.
• W2048507165 hasConceptScore W2048507165C2778720950 @default.
• W2048507165 hasConceptScore W2048507165C2779282312 @default.
• W2048507165 hasConceptScore W2048507165C2779609412 @default.
• W2048507165 hasConceptScore W2048507165C2780007613 @default.
• W2048507165 hasConceptScore W2048507165C2780076729 @default.
• W2048507165 hasConceptScore W2048507165C71924100 @default.
• W2048507165 hasConceptScore W2048507165C90924648 @default.
• W2048507165 hasIssue "7" @default.
• W2048507165 hasLocation W20485071651 @default.
• W2048507165 hasLocation W20485071652 @default.
• W2048507165 hasOpenAccess W2048507165 @default.
• W2048507165 hasPrimaryLocation W20485071651 @default.
• W2048507165 hasRelatedWork W2005348994 @default.
• W2048507165 hasRelatedWork W2010509111 @default.
• W2048507165 hasRelatedWork W2012763953 @default.
• W2048507165 hasRelatedWork W2125469922 @default.
• W2048507165 hasRelatedWork W2395873456 @default.
• W2048507165 hasRelatedWork W2510398055 @default.

• next